Bionano Genomics announced its participation in the American Association for Cancer Research, AACR, Annual Meeting 2024 with a broad range of content covering the utility of OGM for cell bioprocessing quality control, solid tumor and hematological malignancy cancer research. AACR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine. The AACR conference will be held April 5-10, 2024, in San Diego, California. “We are excited to participate in AACR’s annual meeting, where data that will be shared will point to the continued expansion of OGM into clinical research applications for hematological malignancies and solid tumors and highlight progress toward our goal of making OGM an essential tool in the arsenal of cancer researchers. We believe cancer is a disease of structural variation and that OGM and VIA, our software solution which has added features for cancer research and analysis, have the potential to make an impact in the fight against cancer,” commented Erik Holmlin, president and chief executive officer of Bionano.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Genomics announces publication of a breast cancer study with OGM
- Bionano Genomics announces lineup of content at ACMG
- Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company’s New Stratys™ System
- A New Cause for Concern: Bionano Genomics Adds a New Share Price & Shareholder Rights Risk
- Bionano Genomics sees Q1 revenue $8.25M-$8.75M, consensus $9.69M